Product Categories
| Country: | China |
|---|---|
| Tel: | 13720134139 +86 -0-15871494362 |
| Mobile: | 13720134139 |
| E-mail: | |
| QQ: | |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Dacliximab | 152923-56-3 | Details |
| Siltuximab | 541502-14-1 | Details |
| Apalutamide | C21H15F4N5O2S | 956104-40-8 | Details |
| Abemaciclib | C27H32F2N8 | 1231929-97-7 | Details |
| Bevacizumab | C6638H10160N1720O2108S44 | 216974-75-3 | Details |
| Matuzumab | 339186-68-4 | Details |
| Narsoplimab | 2108782-45-0 | Details |
| Lorvotuzumab Mertansine | 1008106-64-6 | Details |
| Alemtuzumab | 216503-57-0 | Details |
| Sarilumab | 1189541-98-7 | Details |
| Research Grade Fontolizumab | 326859-36-3 | Details |
| dupilumab | 1190264-60-8 | Details |
| Labetuzumab | 219649-07-7 | Details |
| Ixekizumab | 1143503-69-8 | Details |
| Nivolumab | 946414-94-4 | Details |
| Ruplizumab | 220651-94-5 | Details |
| Gemtuzumab | 220578-59-6 | Details |
| EFALIZUMABUM | 214745-43-4 | Details |
| Lambrolizumab | 1374853-91-4 | Details |
| Lintuzumab | 166089-32-3 | Details |
| TocilizuMab | C14H12O3 | 375823-41-9 | Details |
| Lymphocide | 205923-57-5 | Details |
| Eculizumab | 219685-50-4 | Details |
| Hu1D10 | 267227-08-7 | Details |
| cantuzumab mertansine | 400010-39-1 | Details |
| Topiroxostat | C13H8N6 | 577778-58-6 | Details |
| Vonoprazan | C17H16FN3O2S | 881681-00-1 | Details |
| Neratinib | C30H29ClN6O3 | 688387-09-6 | Details |
| ApreMilast | C22H24N2O7S | 608141-41-9 | Details |
| Carbazochrome Sodium Sulfonate | C10H17N4NaO8S | 51460-26-5 | Details |
| NEW PRODUCTS INTRODUCTION | Details |
| 1-Methylcyclopropanecarboxylic acid | C5H8O2 | 6914-76-7 | Details |
| Pomalidomide | C13H11N3O4 | 19171-19-8 | Details |
| (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol | C6H12O3 | 14347-78-5 | Details |
| 4,4-dimethyl-3,5,8- trioxabicyclo[5.1.0]octane | C7H12O3 | 57280-22-5 | Details |
| Erlotinib Hydrochloride | C22H23N3O4 | 183321-74-6 | Details |
| Ibrutinib (PCI-32765) | C25H24N6O2 | 936563-96-1 | Details |
| Olaparib | C24H23FN4O3 | 763113-22-0 | Details |
| Crisaborole | C14H10BNO3 | 906673-24-3 | Details |
| Ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate | C18H21NO4S | 161798-03-4 | Details |
| Febuxostat | C16H16N2O3S | 144060-53-7 | Details |
| Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate | C13H13NO3S | 161797-99-5 | Details |
| 4-hydroxythiobenzamide | C7H7NOS | 25984-63-8 | Details |
| Ethyl 2-(3-formyl-4- hydroxyphenyl)-4- methylthiazole-5-carboxylate | C14H13NO4S | 161798-01-2 | Details |
| Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate | C14H12N2O3S | 161798-02-3 | Details |
| Entecavir hydrate | C12H17N5O4 | 209216-23-9 | Details |
| (4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one | C20H20FNO4 | 189028-95-3 | Details |
| Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate | C18H20N2O3S | 160844-75-7 | Details |
| (S)-1-(4-Fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione | C20H18FNO4 | 189028-93-1 | Details |
| Ezetimibe | C24H21F2NO3 | 163222-33-1 | Details |
| Diisopropylamine dichloroacetate | C8H17Cl2NO2 | 660-27-5 | Details |
| Rafivirumab | 944548-37-2 | Details |
| Arcitumomab | 154361-48-5 | Details |
| Gevokizumab | 1129435-60-4 | Details |
| Ranibizumab | C11H12N2O2 | 347396-82-1 | Details |
| Edobacomab | 141410-98-2 | Details |
| Odulimomab | 159445-64-4 | Details |
| Pascolizumab | 331243-22-2 | Details |
| Abagovomab | 792921-10-9 | Details |
| Oregovomab | 213327-37-8 | Details |
| Research Grade T10B9.1A-31 | Details |
| Abciximab | 143653-53-6 | Details |
| Bavituximab | 648904-28-3 | Details |
| Basiliximab | 179045-86-4 | Details |
| Research Grade cT84.66 | Details |
| Nofetumomab | 165942-79-0 | Details |
| Visilizumab | 219716-33-3 | Details |
| Igovomab | 171656-50-1 | Details |
| Mitumomab | 216503-58-1 | Details |
| Research Grade Cc49 | Details |
| Gavilimomab | 244096-20-6 | Details |
| Foravirumab | 944548-38-3 | Details |
| Research Grade Afelimomab | 156227-98-4 | Details |
| Milatuzumab | 899796-83-9 | Details |
| mepolizumab | 196078-29-2 | Details |
| Tadocizumab | 339086-80-5 | Details |
| Pexelizumab | 219685-93-5 | Details |
| Omalizumab | 242138-07-4 | Details |
| Amatuximab | 931402-35-6 | Details |
| nimotuzumab | 828933-51-3 | Details |
| Pertuzumab | C17H27NO2 | 380610-27-5 | Details |
| Motavizumab | 677010-34-3 | Details |
| Naptumomab Estafenatox | 676258-98-3 | Details |
| Inolimomab | 152981-31-2 | Details |
| Research Grade Cedelizumab | 156586-90-2 | Details |
| palivizumab | 188039-54-5 | Details |
| Natalizumab | C40H55N7O11S | 189261-10-7 | Details |
| Edrecolomab | 156586-89-9 | Details |
| Sevirumab | Details |
| Sulesomab | 167747-19-5 | Details |
| Research Grade Immurait-Ll2Mab | Details |
| Tositumomab | 208921-02-2 | Details |
| Iodine (131I) Derlotuximab Biotin | 340013-96-9 | Details |
| Research Grade Tecnemab | Details |
| Enlimomab | 142864-19-5 | Details |
| Biciromab | 138783-13-8 | Details |
| Satumomab | 144058-40-2 | Details |
| Imciromab | 126132-83-0 | Details |
| Siplizumab | 288392-69-8 | Details |
| Capromab | C10H15N5O11P2 | 145464-28-4 | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 | ||||